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Abstract Ten overlapping 15-mer peptides (peptidyl amides) 
spanning the proregion of rat cathepsin B (residues lp-60p) were 
constructed to identify minimal segments having inhibitory 
activity towards the mature enzyme, that could be used to 
develop a new generation of peptide-derived inhibitors specifi- 
cally targeting the active site of the corresponding proteinase. 
Three synthetic peptides, containing the pentapeptide Leu-Cys- 
Gly-Thr-Val (residues 41p-45p) in their sequence, inhibited 
cathepsin B with Ki values in the micromolar ange. Alkylation of 
the thiol group of Cys-42p of peptide PB8 (36p-50p) resulted in 
its rapid proteolytic degradation, suggesting that this residue is 
essential for inhibition. The inhibition constant was slightly 
improved (Kt = 2 ltM) using a longer peptide (26p-50p) which 
was completely resistant to cleavage even after a prolonged 
incubation. Alkylation of its cysteinyl residue also resulted in 
rapid cleavage of the peptide chain. Peptides derived from the rat 
cathepsin B prosequence also inhibited human cathepsin B with 
similar Kl values. Unlike rat cathepsin B, which cleaves peptide 
PB8 at the G47p-G48p bond after prolonged incubation, the 
human enzyme cleaved both PB8 and PBl l  at the Lys-40p-Leu- 
41p bond, in agreement with the different kinetic properties of 
these two proteinases. New probes with improved specificity for 
cysteine proteinases may therefore be designed based on the 
sequences of their propeptides. 
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1. Introduction 
Mature cathepsin B is involved in a variety of biological 
processes, such as the intracellular degradation of endocy- 
tosed and endogenous proteins, bone resorption, and in 
pathologic events uch as rheumatoid arthritis, tumor metas- 
tasis, or muscular dystrophy (see [8] for review). The proen- 
zyme has a propeptide of = 60 residues, which is significantly 
shorter than the propeptides of papain and cathepsin L [9]. 
Maturation of cathepsin B occurs via an autocatalytic uni- 
molecular mechanism [10]. The resulting 6-kDa propeptide 
and the 30-kDa single chain enzyme form a non-covalent 
complex, which may stabilize the processed proteinase at neu- 
tral pH [11]. The rat cathepsin B proregion is a potent slow- 
binding reversible inhibitor of the mature enzyme [12] that 
may control its proteolytic activity physiologically. The recent 
elucidation of the 3D structures of human and rat procathep- 
sin B is an essential step towards understanding the way the 
mature enzyme is inhibited by its propeptide. Three major 
areas in the protease take part in the interaction; two of 
them, a prosegment binding loop (PBL) and an occluding 
loop crevice, are remote from the active site, while the third 
is the substrate binding cleft [13,14]. However, whether all are 
required for inhibition or whether a minimal segment in the 
proregion can specifically interact with the corresponding en- 
zyme is not known. We have attempted to answer this ques- 
tion by constructing overlapping peptides panning the whole 
proregion of rat cathepsin B, and measuring their capacities to 
inhibit mature rat and human enzymes. 
Most of the proteinases from all four classes (metallopro- 
teases, aspartic, serine, and cysteine proteases) are synthesized 
as pre-pro-enzymes that are converted to their mature active 
forms by proteolytic leavage of the proregion. Whereas the 
activation of some serine proteinases that have short prore- 
gions, like trypsin and chymotrypsin, is well known, it is less 
clear for enzymes with longer proregions ( > 60 residues). The 
proregions of these proteinases are essential for such physio- 
logical functions as intracellular t afficking, correct folding of 
the enzyme during maturation, and inhibition of the mature 
enzyme [1-5]. The inhibition of proteinases by their respective 
proregions i a rather specific process [6,7], and this relation- 
ship can be used to develop a new generation of specific pep- 
tide inhibitors. The cysteine proteinases of the papain family 
are particularly appropriate targets for such a strategy, since 
no specific synthetic substrates and inhibitors are available to 
follow the activity of individual members. 
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Abbreviations." Acm, 5-acetamidomethyl; AMC, 7-amino-4-methyl- 
coumarin. 
2. Material and methods 
2.1. Peptide synthesis 
Unless otherwise stated, all amino acids were of the L-configuration, 
and were purchased from NovaBiochem (FranceBiochem, Meudon), 
or Neosystem (Strasbourg, France). Peptides were prepared simulta- 
neously using a Zinsser solid-phase multisynthesizer (Advanced 
ChemTech GmbH, Frankfurt, Germany). Synthesis was performed, 
using a Rink Amide MBHA ((4-(2',4'-dimethoxyphenyl-Fmoc-amino- 
methylphenoxyacet midonorleucyl)-4-methylbenzhydrylamine) resin 
(NovaBiochem), by Fmoc chemistry [15]. After deprotection and 
cleavage, peptidyl amides were purified by gel filtration on a Sephadex 
G-25 column (Pharmacia) equilibrated in 5% acetic acid, and their 
homogeneity checked by reverse-phase chromatography on a C18 OD 
300 cartridge (Brownlee), using a 30-min linear (0-60%) acetonitrile 
gradient in 0.1% trifluoroacetic a id. Elution was monitored by an 
Applied Biosystems 1000S diode array detector (Perkin Elmer-France, 
Roissy). 
An alkylated form of peptide PB8, peptide PB8A .... was prepared 
by Fmoc chemistry (synthesizer Applied Biosystems 431 A). An S- 
acetamidomethyl group (Acm) was used to block the cysteinyl thiol 
group. After cleavage and deprotection, peptide PB8Acm was purified 
by gel filtration on Sephadex G-25, as described above. Alternatively, 
the S-acetamidomethyl group was removed by mercuric acetate ac- 
cording to Lamthanh et al. [16], then checked by MALDI-TOF mass 
spectroscopy (Briiker). Deprotection fPB8Acnl gave its reduced form, 
peptide PB8. The purity of the peptides was checked by RP-HPLC on 
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a C18 OD 300 Brownlee cartridge, using a 30 min linear (0 60%) 
acetonitrile gradient in 0.1% trifluoroacetic a id. Peptide molecular 
weights were determined by mass pectroscopy. Peptides PB11 (resi- 
dues 26p-50p) and PB11Acre were prepared by the same procedure. 
2.2. Enzymes 
Rat liver cathepsin B was purified as previously described [17]. 
Recombinant human cathepsin B was a gift from Dr. John S. Mort 
(McGill University, Montreal, Canada). Cathepsin B was assayed on 
Z-Phe-Arg-AMC (Bachem Biochimie, Voisins-le-Bretonneux, France), 
and the enzymatic activity was recorded in a spectrofluorometer, with 
wavelengths of 350 and 460 nm for excitation and emission. Assays 
were carried out in activating buffer: 0.1 M phosphate buffer pH 6.0, 
containing 1mM EDTA, 2 mM dithiothreitol, 0.1% Brij 35. Cysteine 
proteinases were titrated with L-3-carboxy-trans-2,3-epoxypropionyl- 
leucylamido(4-guanidino)butane (E-64) [18]. 
2.3. Kinetic measurements 
All peptides were screened for their inhibitory capacity by micro- 
fluorimetry (Dynatech microreader). Cathepsin B (1.2 nM) was incu- 
bated with peptides (10/aM), in the activating buffer, at 37°C for 10 
min, in a microfluor plate, in a final volume of 100/al; the enzymatic 
reaction was triggered by adding Z-Phe-Arg-AMC (20/aM), and the 
residual enzymatic activity was recorded. The screening was repeated 
with a peptide concentration f 1 p.M. Any peptides showing signifi- 
cant inhibition under the above conditions were selected, and their 
inhibitory constants (Ki) calculated by the method of Dixon [19]. 
2.4. Peptide stability 
The stability of the peptides in the presence of cathepsin B was 
checked by incubating proteinase (4.8 nM) and peptides (30 /aM) in 
the assay buffer (0.1 M phosphate buffer pH 6.0, 1 mM EDTA, 2 mM 
dithiotreitol, 0.1% Brij 35), at 37°C for 0-240 min (molar ratio en- 
zyme/peptide: 1 6250). Samples were fractionated by reverse-phase 
chromatography ona C18 Brownlee cartridge, using a linear 0-60% 
gradient of acetonitrile in 0.075% TFA. The elution profiles were 
analyzed by Spectacle (PC 1000 version 3.0) (Thermo Separation 
Products, Les Ulis, France), and the hydrolysis products were identi- 
fied by MALDI-TOF mass pectroscopy. 
3. Results and discussion 
Ten 15-mer peptides (peptides PB1-PBI0), spanning the rat 
procathepsin B sequence (residues lp--60p) (Table 1), were 
synthesized as peptidyl amides by a multisynthesis procedure. 
Their capacities to inhibit rat cathepsin B were assayed by 
measuring the residual enzymatic activity on Z-Phe-Arg- 
AMC. Only three of these peptides (PB7-PB9) inhibited rat 
cathepsin B. Their Ki values were determined using the Dixon 
plot, and were all in the micromolar range, the lowest value 
being for peptide PB8 (Table 2). All 3 peptides behaved as 
competitive inhibitors of cathepsin B and no significant cleav- 
Table 1 
Overlapping synthetic peptides panning the proregion of rat ca- 
thepsin B a 
~p 62p 
HDKPSFHPLS DDMINYINKQ NTTWQAGRNF yNVDISYLKK LCGTVLGGPK LPERVGFSED IN 
(i) 
PBI 
PB2 
PB3 
PB4 
PB5 
PB6 
pB7 
PB8 
PB9 
PBI0 
12) 
PBII 
HDKPSFHPLSDDMIN 
FHPLSDDMINYINKQ 
DDMINYINKQNTTWQ 
YINKQNTTWQAGRNF 
NTTWQAGRNFYNVDI  
AGRNFYNVDISYLKK 
YNVDISYLKKLCGTV 
SYLKKLCGTVLGGPK 
LCGTVLGGPKLPERV 
LGGPKLPERVGFSED 
AGRNFYNVDISYLKKLCGTVLGGPK 
~Residue number of rat procathepsin B [13]. 
Table 2 
Equilibrium dissociation constants for the inhibition of cathepsin B
by rat pro-cathepsin B peptides 
Peptides Ki (/aM) 
Rat Human 
PB1 nsi 
PB2 nsi 
PB3 nsi - 
PB4 nsi - 
PB5 nsi 
PB6 nsi 
PB7 12.5 
PB8 4.6 14.6 
PB9 11.6 - 
PB10 nsi - 
PBI1 2 2.8 
PB8 Acm nsi nsi 
PBll Acm (b) 12.5 11.0 
nsi, no significant inhibition. Kinetic measurements were performed as 
described in Section 2. 
age occurred uring the course of the experiment, asshown by 
reverse-phase HPLC, using an identical peptide/cathepsin B 
molar ratio. However, a cleavage site was identified by mass 
spectrometry at the G47p-G48p bond, after incubation for 
1 h. The sequence ncompassing this scissile bond in the pro- 
segment is reminiscent of that of the substrate-like s quence in 
human cystatin C [20], from which sensitive fluorogenic a- 
thepsin B substrates have been constructed [21,22]. It is also 
similar to the autocatalytic activation site of some parasitic 
cysteine proteinases of the papain family [23]. The sequences 
of peptides PB7-PB9 all include the pentapeptide LCGTV 
corresponding to residues 41p-45p of the prosequence. One 
or more residue(s) in this sequence are therefore ssential for 
the interaction with the catalytic site of the mature enzyme. 
This agrees with crystallographic data showing that interac- 
tion of the proregion with rat cathepsin B involves residues 
Leu-41p-Gly-47p which are deeply buried in the substrate 
binding site [13]. According to these data and those for hu- 
man cathepsin B [13,14], Cys-42p, which is the residue closest 
to the oxyanion hole, significantly contributes to propeptide 
binding by interacting with several hydrophobic groups of 
cathepsin B. Alkylation of Cys-42p in peptide PB8 resulted 
in a loss of inhibition (peptide PB8Acm). Peptide PB8Acm was 
also cleaved at the G47p-G48p site upon incubation with 
cathepsin B, but much more rapidly than peptide PBS. This 
may be because the 5-acetamidomethyl group of the PB8Acm 
peptide impairs fitting of the cysteinyl group due to steric 
hindrance. Alternatively, the more hydrophilic nature of 
PB8Acm peptide after alkylation, as deduced from its signifi- 
cantly shorter etention time on a C18 reverse phase cartridge 
(results not shown), could modify the interaction with the 
hydrophobic subsite. Competition would therefore occur be- 
tween the LVGG substrate-like r gion and the inhibitory site. 
The K~ values obtained with peptides PB7-PB9 are greater 
than that in the nM range reported for a peptide spanning 
almost he entire proregion of cathepsin B (residues lp-56p) 
[12]. This suggests that the other two regions in the proseg- 
ment, contributing to the tight binding of cathepsin B with its 
prosegment, are also involved in the inhibition. A 25-mer 
peptide (PB11) (residues 26p-50p), corresponding to peptide 
PB8 plus a 10-residue N-terminal extension, and including the 
region of interaction with the occluding loop crevice in ca- 
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thepsin B, was synthesized and its inhibiting capacity assayed. 
The Ki was only slightly improved (Ki = 2 laM) but the peptide 
was completely resistant to proteolysis, even after incubation 
overnight. It may appear surprising that a 25 residue long 
peptide is resistant o proteolysis by cathepsin B, the broad 
specificity of which has been well demonstrated [24]. It may be 
because the peptide is oriented in the reverse position com- 
pared to a natural peptide substrate. This reverse orientation 
has been described for the interaction between cathepsin B 
and its proregion in the rat procathepsin B crystal [13], and 
it also corresponds to the orientation of E 64 and its deriva- 
tives with papain and cathepsin B[25-28]. This explanation is
supported by the observation that the same peptide with an 
alkylated cysteinyl residue (PB11Acre) is more rapidly and un- 
specifically degraded by cathepsin B. Peptide PBl l  therefore 
contains cleavage sites, but they are not accessible. This also 
demonstrates the pivotal role of the cysteinyl residue in the 
interaction. However, the Ki obtained using the PB11 peptide 
is still higher than that with the PCB1 peptide [12], suggesting 
that the peptidyl chain cannot adopt the anchoring structure 
needed to maintain intimate contacts with cathepsin B, even 
though it is correctly oriented at the cathepsin B surface. 
The above experiments were repeated using human ca- 
thepsin B, the propeptide of which is similar to that of the 
rat and other mammals [29], especially in the region including 
the conserved Cys 42p residue. Peptide PB8, which is derived 
from the rat prosequence, inhibited the human enzyme with a 
slightly higher Ki, while the Ki was similar with PB11. How- 
ever, the cleavage site revealed after prolonged incubation 
with the human enzyme was at the Lys-40p Leu-41p bond 
in both peptides PB8 and PB11, which differs from that ob- 
tained with rat cathepsin B. This agrees with the somewhat 
different kinetic properties of the two proteinases that hydro- 
lyse synthetic substrates at different rates [24]. We recently 
showed that a substrate with intramolecularly quenched fluor- 
escence (Abz-LVGGP-EDDnp), derived from the substrate- 
like region of human cystatin C [20], is less efficiently hydro- 
lysed by human cathepsin B than by its rat homologue (un- 
published results). This explains the selective cleavage of the 
homologous equence in peptides PB8 and PBl l  by the rat 
proteinase after prolonged incubation. The close proximity of 
the Lys-40p-Leu-41p bond to the essential Cys-42p residue 
may explain why alkylation of the latter impairs cleavage by 
human cathepsin B. 
These results how that the entire proregion of procathepsin 
B is not required for interaction with the mature enzyme, but 
that a short sequence containing a critical cysteinyl residue is 
sufficient o interact with, and inhibit both human and rat 
cathepsin B. However, this inhibition does not compare with 
that obtained with the whole propeptide, suggesting that other 
regions are essential to optimize peptide conformation and/or 
positioning at the surface of the mature enzyme. The segment 
upstream of the inhibitory sequence in the proregion, which 
acts as a short anchoring two-turn ct-helix (residues 35p~llp) 
in rat procathepsin B [13], improves inhibition, probably by 
favouring the binding such as in the prosegment of procathep- 
sin B. This explains the resistance of peptide PB11 to cleavage 
by the mature enzyme. The results obtained here using over- 
lapping peptides panning the cysteine proteinase proregion 
agree with those reported from crystal structures of human 
and rat procathepsin B [13,14]. This promising approach to 
designing more selective inhibitors of cysteine proteinases will 
be extended to the proregions of other papain-like protein- 
ases, especially those of protozoan parasites like trypano- 
somes, that are involved in both spreading and host infection 
[30,31], but have no specific substrate or inhibitors that can 
selectively control their activity. 
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